Patentability filed 7 Jan 2022 in the United States Court of Appeals for the Federal Circuit and closed 10 Aug 2023, with US20180201664A1 asserted. Recorded basis of termination: vacated and remanded.
Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.
22-1346 is a patent patentability brought by Theripion, Inc. against Katherine K. Vidal, filed on 7 Jan 2022 in the United States Court of Appeals for the Federal Circuit. The case closed on 10 August 2023.
Which patent was asserted in 22-1346?
US20180201664A1 (“APOA-1 fusion polypeptides and related compositions and methods”), assigned to THERIPION, INC., currently active. The record also lists APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS.
How was case 22-1346 terminated?
The recorded basis of termination is vacated and remanded. The termination text reads: "THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: VACATED AND REMANDED"
How long did case 22-1346 take?
580 calendar days, from filing on 7 Jan 2022 to closure on 10 August 2023.
Who were the attorneys and the judge in 22-1346?
Jill Browning and Nicholas V. Sherbina are recorded as counsel for plaintiff Theripion. Amy J. Nelson, Farheena Yasmeen Rasheed Deputy Solicitor, Mary L. Kelly, Robert Mcbride Associate Solicitor and Thomas W. Krause appear for defendant Katherine K. Vidal.
Answers reproduce fields from the case record for 22-1346 and do not constitute legal advice.Ask your own question
Disclaimer. This page reproduces publicly available court docket data for case 22-1346 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.
